US Women’s Health Laboratory Testing Market
Dublin, Feb. 17, 2023 (GLOBE NEWSWIRE) — The “US Women’s Health Laboratory Testing Market – A Region Wise Analysis: Focus on the US Women’s Health Laboratory Testing Market – Analysis and Forecast, 2022-2030” the report has been added to ResearchAndMarkets.com’s The offer of
The US women’s health laboratory testing market was valued at USD 72.8 billion in 2021 and is projected to reach USD 106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030.
The market is driven by factors such as increasing prevalence of infectious diseases and cancer among women, increasing awareness regarding women’s health screenings, increasing average maternal age leading to increased risk of fetal chromosomal aneuploidy, and increasing health reproductive. problems leading to increased demand for laboratory testing in women.
The U.S. women’s health laboratory testing market is in a nascent stage. Advances in diagnostic technologies including applications of genetic testing in women’s health and the significant number of mergers and acquisitions of companies to achieve a better market share are some of the major opportunities in the US women’s health laboratory testing market. .
How can this report add value to an organization?
Different segment of the report helps the reader to understand the different types of Women’s Health Lab Tests/Services available in the market.
Furthermore, the study provides the reader with a detailed understanding of the tests/services involved in various segments, which are hereditary cancer, carrier screening, prenatal screening and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology. .
Growth/Marketing Strategy: The US women’s health laboratory testing market has witnessed major development by key players operating in the market such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, activities of financing and regulatory and legal approvals.
The favored strategy for companies has been regulatory and legal activities to strengthen the position of their product in the US market. For example, in October 2019, Myriad Genetics, Inc. announced that the US Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic to Zejula treatment in late-line ovarian cancer.
The report attribute
number of pages
2022 – 2030
Estimated market value (USD) in 2022
76.2 billion dollars
Projected market value (USD) by 2030
106.8 billion dollars
Compound Annual Growth Rate
Recent Developments in the US Women’s Health Laboratory Testing Market
In November 2022, Roche Holdings launched the Cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the US. The system can help diagnose infectious diseases, such as HIV, hepatitis, transplant-related viral and respiratory diseases. and STIs.
In February 2022, Laboratory Corporation of America Holdings formed a strategic partnership with Ascension to expand its testing capabilities.
In January 2022, Yourgene announced that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc, a point-of-care business with accredited laboratory testing capabilities in the US
In November 2022, Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.
In August 2022, Natera, Inc. announced that the company has proactively submitted a submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.
The US women’s health (hereditary cancer) laboratory testing market is expected to be dominated by the cervical cancer segment.
The US women’s health laboratory tests (prenatal screening and diagnostic testing) market is dominated by the non-invasive prenatal testing segment.
The US women’s health laboratory testing market (reproductive health and infectious diseases) is dominated by the HIV testing segment.
The US women’s health laboratory testing market (by region) is dominated by the southern region segment.
Main topics covered:
1.1 US market outlook
1.1.1 Product Definition
1.1.2 Inclusion and exclusion criteria
1.2 Business dynamics
1.2.1 Impact analysis
1.2.2 Business leaders
220.127.116.11 Increasing prevalence of infectious diseases and cancer in women leading to increased demand for laboratory diagnostics
18.104.22.168 Raising awareness about tests related to women’s health
22.214.171.124 Increasing average maternal age leading to increased risk of fetal chromosomal aneuploidy
126.96.36.199 Increasing reproductive health problems leading to increased demand for laboratory testing among women
1.2.3 Business Limitations
188.8.131.52 Strict regulatory guidelines regarding laboratory testing hindering market growth in the US
184.108.40.206 Disparity in Awareness of Pregnancy and Fertility Issues in Different US Regions
1.2.4 Business Opportunities
220.127.116.11 Advances in diagnostic technologies, including applications of genetic testing in women’s health
18.104.22.168 Health care disparities in rural US counties
22.214.171.124 The gap in health care for women of reproductive age with psychological concerns
126.96.36.199 Significant number of mergers and acquisitions by companies to achieve a better market share
2 US Women’s Health Laboratory Testing Market (by Hereditary Cancer)
2.2 Breast cancer
2.2.2 Test market
2.2.3 Testing market (by region)
2.3 Cervical cancer
2.4 Ovarian cancer
3 US Women’s Health Laboratory Testing Market (By Operator Examination)
3.1.1 Test market
3.1.2 Testing market (by region)
4 US Women’s Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)
4.2 Non-invasive prenatal testing (NIPT)
4.3 Maternal serum screening (MSS)
4.4 Prenatal diagnostic testing
5 US Women’s Health Laboratory Testing Market (from Reproductive Health & Infectious Diseases)
5.2 Pregnancy and ovulation testing
5.3 HPV Testing
5.4 PAP Smear Testing
5.5 HIV Testing
5.6 CT/NG Testing
5.7 Pre-implantation genetic testing (PGT)
5.8 Sexually transmitted infections (syphilis, gonorrhea, chlamydia)
5.9 Herpes Simplex Virus (HSV)
5.11 Vaginal infections
6 US Women’s Health Laboratory Testing Market (from Obstetrics and Gynecology)
6.1.1 Testing market (by region)
For more information about this report visit https://www.researchandmarkets.com/r/wyrvwd-s-women-health?w=12
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, top industries, top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Leave a Reply